Lexaria Bioscience Corp.
Lexaria Bioscience Corp.
08/17/2026 | Press release | Distributed by Public on 08/17/2026 10:38
Material Event (Form 8-K)
|
Item 8.01 |
Other Events |
Cure of Nasdaq Bid Price Deficiency
On August 17, 2026, Lexaria Bioscience Corp. (the "Company") received a letter from the Hearings Advisor of The Nasdaq Stock Market ("Nasdaq") advising that the Nasdaq Listings Qualifications Staff had confirmed that the Company had regained compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2). Consequently, the previously requested hearing has been cancelled and the Company's Common Stock will continue to be listed and trading on The Nasdaq Capital Market.
|
2 |
Lexaria Bioscience Corp. published this content on August 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 17, 2026 at 16:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]